In patients with T2D and multiple risk factors for ASCVD but without established disease, meta-analyses have not detected a MACE benefit for GLP-1RA or SGLT2 inhibitors.69 Other considerations may include the type of background ASCVD. This evidence concerns the gene SLC5A2 and atherosclerosis.